Logo image of GOSS

GOSSAMER BIO INC (GOSS) Stock Fundamental Analysis

NASDAQ:GOSS - Nasdaq - US38341P1021 - Common Stock - Currency: USD

1.36  0 (0%)

After market: 1.37 +0.01 (+0.74%)

Fundamental Rating

3

GOSS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. GOSS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, GOSS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GOSS had negative earnings in the past year.
GOSS had a positive operating cash flow in the past year.
GOSS had negative earnings in each of the past 5 years.
In the past 5 years GOSS always reported negative operating cash flow.
GOSS Yearly Net Income VS EBIT VS OCF VS FCFGOSS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

GOSS has a Return On Assets of -18.26%. This is in the better half of the industry: GOSS outperforms 78.64% of its industry peers.
Industry RankSector Rank
ROA -18.26%
ROE N/A
ROIC N/A
ROA(3y)-53.25%
ROA(5y)-54.59%
ROE(3y)-791.28%
ROE(5y)-528.46%
ROIC(3y)N/A
ROIC(5y)N/A
GOSS Yearly ROA, ROE, ROICGOSS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 0 0 0 0 0 0 0 0 0 0

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GOSS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GOSS Yearly Profit, Operating, Gross MarginsGOSS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

More info and screens

4

2. Health

2.1 Basic Checks

GOSS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GOSS has more shares outstanding
Compared to 5 years ago, GOSS has more shares outstanding
The debt/assets ratio for GOSS has been reduced compared to a year ago.
GOSS Yearly Shares OutstandingGOSS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
GOSS Yearly Total Debt VS Total AssetsGOSS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

GOSS has an Altman-Z score of -5.09. This is a bad value and indicates that GOSS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -5.09, GOSS is not doing good in the industry: 60.50% of the companies in the same industry are doing better.
GOSS has a debt to FCF ratio of 21.77. This is a negative value and a sign of low solvency as GOSS would need 21.77 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 21.77, GOSS belongs to the top of the industry, outperforming 91.38% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 21.77
Altman-Z -5.09
ROIC/WACCN/A
WACC9.21%
GOSS Yearly LT Debt VS Equity VS FCFGOSS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 5.71 indicates that GOSS has no problem at all paying its short term obligations.
GOSS's Current ratio of 5.71 is in line compared to the rest of the industry. GOSS outperforms 59.43% of its industry peers.
GOSS has a Quick Ratio of 5.71. This indicates that GOSS is financially healthy and has no problem in meeting its short term obligations.
GOSS has a Quick ratio of 5.71. This is in the better half of the industry: GOSS outperforms 60.32% of its industry peers.
Industry RankSector Rank
Current Ratio 5.71
Quick Ratio 5.71
GOSS Yearly Current Assets VS Current LiabilitesGOSS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 78.30% over the past year.
EPS 1Y (TTM)78.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GOSS will show a very strong growth in Earnings Per Share. The EPS will grow by 23.83% on average per year.
The Revenue is expected to grow by 25.84% on average over the next years. This is a very strong growth
EPS Next Y-165.3%
EPS Next 2Y-39.2%
EPS Next 3Y12.03%
EPS Next 5Y23.83%
Revenue Next Year-74.47%
Revenue Next 2Y-30.14%
Revenue Next 3Y5.21%
Revenue Next 5Y25.84%

3.3 Evolution

GOSS Yearly Revenue VS EstimatesGOSS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
GOSS Yearly EPS VS EstimatesGOSS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GOSS. In the last year negative earnings were reported.
Also next year GOSS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GOSS Price Earnings VS Forward Price EarningsGOSS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

93.36% of the companies in the same industry are more expensive than GOSS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 34.03
EV/EBITDA N/A
GOSS Per share dataGOSS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

GOSS's earnings are expected to grow with 12.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-39.2%
EPS Next 3Y12.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GOSS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GOSSAMER BIO INC

NASDAQ:GOSS (7/11/2025, 8:19:06 PM)

After market: 1.37 +0.01 (+0.74%)

1.36

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners76.01%
Inst Owner Change0%
Ins Owners0.76%
Ins Owner Change0%
Market Cap309.13M
Analysts82.67
Price Target7.76 (470.59%)
Short Float %5.05%
Short Ratio5.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.92%
Min EPS beat(2)13.49%
Max EPS beat(2)16.34%
EPS beat(4)3
Avg EPS beat(4)7.79%
Min EPS beat(4)-5.81%
Max EPS beat(4)16.34%
EPS beat(8)7
Avg EPS beat(8)7.86%
EPS beat(12)9
Avg EPS beat(12)5.81%
EPS beat(16)12
Avg EPS beat(16)4.47%
Revenue beat(2)2
Avg Revenue beat(2)86.44%
Min Revenue beat(2)34.54%
Max Revenue beat(2)138.35%
Revenue beat(4)3
Avg Revenue beat(4)43.95%
Min Revenue beat(4)-17.78%
Max Revenue beat(4)138.35%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)22.53%
PT rev (3m)19.33%
EPS NQ rev (1m)-1.4%
EPS NQ rev (3m)5.44%
EPS NY rev (1m)-1.61%
EPS NY rev (3m)4.75%
Revenue NQ rev (1m)-14.8%
Revenue NQ rev (3m)1.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)27.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.48
P/FCF 34.03
P/OCF 33.93
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)0.04
FCFY2.94%
OCF(TTM)0.04
OCFY2.95%
SpS0.55
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.26%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 7.29%
ROA(3y)-53.25%
ROA(5y)-54.59%
ROE(3y)-791.28%
ROE(5y)-528.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 21.77
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.71
Quick Ratio 5.71
Altman-Z -5.09
F-Score6
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)7.47%
Cap/Depr(5y)43.57%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.79%
EPS Next Y-165.3%
EPS Next 2Y-39.2%
EPS Next 3Y12.03%
EPS Next 5Y23.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-74.47%
Revenue Next 2Y-30.14%
Revenue Next 3Y5.21%
Revenue Next 5Y25.84%
EBIT growth 1Y67.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-131.67%
EBIT Next 3Y34.35%
EBIT Next 5Y34.99%
FCF growth 1Y104.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y104.88%
OCF growth 3YN/A
OCF growth 5YN/A